{"log_id": 440884607718242328, "direction": 0, "words_result_num": 128, "words_result": [{"probability": {"variance": 0.023074, "average": 0.919002, "min": 0.359567}, "location": {"width": 694, "top": 74, "height": 35, "left": 812}, "words": "险。因此,对于糖尿病患者有妊娠尿史的患者,在孕前及整个怀孕过程"}, {"probability": {"variance": 0.027152, "average": 0.905461, "min": 0.392074}, "location": {"width": 648, "top": 93, "height": 58, "left": 113}, "words": "唑二酮类的另一类药物曲格列酮在临床应用中与特异性肝脏毒性有关,且有"}, {"probability": {"variance": 0.002421, "average": 0.955748, "min": 0.880898}, "location": {"width": 81, "top": 104, "height": 20, "left": 111}, "words": "肝脏反应"}, {"probability": {"variance": 0.010732, "average": 0.96218, "min": 0.454346}, "location": {"width": 688, "top": 96, "height": 34, "left": 812}, "words": "中维持良好的代谢控制非常重翼。对此类患者应严密监测其血控制。专家推"}, {"probability": {"variance": 0.039191, "average": 0.875366, "min": 0.350212}, "location": {"width": 652, "top": 113, "height": 81, "left": 111}, "words": "超过正常上限3倍的发生率安慰剂维高,少数可逆性黄水见报LT水平"}, {"probability": {"variance": 0.017979, "average": 0.907908, "min": 0.541538}, "location": {"width": 612, "top": 119, "height": 53, "left": 113}, "words": "肝功能竭、肝移植及死亡的罕见报告,在对照试验中,曲格列组ALT"}, {"probability": {"variance": 0.018215, "average": 0.933628, "min": 0.457264}, "location": {"width": 606, "top": 114, "height": 38, "left": 812}, "words": "荐在怀孕期间使玛胰岛素单药治疗以维持血糖水平尽可能接近正常值"}, {"probability": {"variance": 0.010554, "average": 0.95549, "min": 0.508729}, "location": {"width": 685, "top": 143, "height": 29, "left": 815}, "words": "已报告木品可通过人胎盘屏障,且可在胎儿组织中测出,尚无足够的人类妊姬"}, {"probability": {"variance": 0.02247, "average": 0.929993, "min": 0.412296}, "location": {"width": 636, "top": 162, "height": 53, "left": 111}, "words": "在共有4598例患者接受本吊治疗的多项试验中,服用时间约为3600病人"}, {"probability": {"variance": 0.031522, "average": 0.888717, "min": 0.434586}, "location": {"width": 679, "top": 165, "height": 26, "left": 819}, "words": "l乳期使用品的资料,怀孕间不应用本品。本品可使伴有岛案打抗"}, {"probability": {"variance": 0.012432, "average": 0.951046, "min": 0.491068}, "location": {"width": 526, "top": 196, "height": 40, "left": 113}, "words": "年,无证据表明有药物所的肝毒性反应或ALT水平升高发生"}, {"probability": {"variance": 0.019266, "average": 0.926708, "min": 0.361503}, "location": {"width": 689, "top": 184, "height": 34, "left": 813}, "words": "的绝经前期和无排卵型妇女恢女排卵,四此建议患者服用本品,需采取避孕"}, {"probability": {"variance": 0.007156, "average": 0.962322, "min": 0.528833}, "location": {"width": 657, "top": 204, "height": 55, "left": 111}, "words": "在对照试验中,ALT水平超过正常上限3倍的发生率分别为;马米酸罗格列酮组"}, {"probability": {"variance": 0.027507, "average": 0.886239, "min": 0.405193}, "location": {"width": 658, "top": 229, "height": 50, "left": 111}, "words": "0.2%、安慰剂.2%,阳性对照组0.5%服用马来酸罗格列者的ALT升高"}, {"probability": {"variance": 0.000305, "average": 0.991134, "min": 0.938622}, "location": {"width": 543, "top": 229, "height": 26, "left": 821}, "words": "儿童用药】儿童使用本品的安全性及有效性的资料尚末建立"}, {"probability": {"variance": 0.002476, "average": 0.965834, "min": 0.807028}, "location": {"width": 417, "top": 269, "height": 32, "left": 111}, "words": "均为可逆性、且与服用本品的果关系不确定"}, {"probability": {"variance": 0.009439, "average": 0.960181, "min": 0.473156}, "location": {"width": 673, "top": 250, "height": 32, "left": 828}, "words": "老年月药】群体药代动力学分析结果表明,年龄对罗格列酮的药代动力学无"}, {"probability": {"variance": 0.004807, "average": 0.957169, "min": 0.762009}, "location": {"width": 652, "top": 271, "height": 53, "left": 111}, "words": "本品上市后,有肝炎和肝酶升高大于3倍的报:在这些报告的病例中,虽然"}, {"probability": {"variance": 0.008606, "average": 0.946208, "min": 0.651208}, "location": {"width": 686, "top": 274, "height": 28, "left": 818}, "words": "正著影响《海见[临床药代动力学]特殊人),因此老年思者服用本品时毋需"}, {"probability": {"variance": 0.037831, "average": 0.827775, "min": 0.363628}, "location": {"width": 642, "top": 296, "height": 47, "left": 111}, "words": "因果关乐并未确立,但罕见有威胁或不城胁生命的功能衰的报告。罗"}, {"probability": {"variance": 0.028981, "average": 0.892082, "min": 0.448179}, "location": {"width": 542, "top": 296, "height": 25, "left": 813}, "words": "囚年龄面整剂量。在临床对照试验中,老年组(≥百5岁"}, {"probability": {"variance": 0.015963, "average": 0.93086, "min": 0.48456}, "location": {"width": 654, "top": 317, "height": 47, "left": 111}, "words": "列在化学结构上与格列酮相关,曲格列在临床应用中与特异性肝专性有"}, {"probability": {"variance": 0.020358, "average": 0.920872, "min": 0.444071}, "location": {"width": 682, "top": 296, "height": 53, "left": 819}, "words": "65岁)在药物的安全性与有效性方面未观察到总体上的差与成人组("}, {"probability": {"variance": 0.028108, "average": 0.905375, "min": 0.448545}, "location": {"width": 646, "top": 341, "height": 44, "left": 113}, "words": "关,且有肝功能衰竭、非移植及死亡的罕见报沾,现已退出美国市场,控于"}, {"probability": {"variance": 0.019554, "average": 0.936931, "min": 0.366514}, "location": {"width": 704, "top": 341, "height": 29, "left": 813}, "words": "【药物相互作用】经细胞色素P40代谢的药物体外药物代试验表明,在临床使"}, {"probability": {"variance": 0.037778, "average": 0.879013, "min": 0.37315}, "location": {"width": 636, "top": 366, "height": 41, "left": 108}, "words": "明确罗格列酮肝脏安全性的一些大规捞的对临床试验结果及上市后床"}, {"probability": {"variance": 0.023126, "average": 0.915469, "min": 0.443578}, "location": {"width": 694, "top": 359, "height": 38, "left": 816}, "words": "日剂量下,罗格列不抑制主的P15,休外试验资料证实,罗格列酮主要"}, {"probability": {"variance": 0.010561, "average": 0.946394, "min": 0.645434}, "location": {"width": 543, "top": 393, "height": 37, "left": 111}, "words": "用安全性资料正在收集中,故推服川本品的患者定期测肝功"}, {"probability": {"variance": 0.010638, "average": 0.933316, "min": 0.669604}, "location": {"width": 323, "top": 385, "height": 23, "left": 818}, "words": "新过代谢,极少部分经CP2C9代谢"}, {"probability": {"variance": 0.024107, "average": 0.899384, "min": 0.356076}, "location": {"width": 630, "top": 411, "height": 40, "left": 111}, "words": "病人开始服用本品前应检肝胜转氨,服药后根医生医定期查"}, {"probability": {"variance": 0.025242, "average": 0.912358, "min": 0.35362}, "location": {"width": 691, "top": 406, "height": 26, "left": 819}, "words": "木品与c:2CE抑制剂如吉非贝齐)联合用药,可能升高罗格列酶血浆浓度(参"}, {"probability": {"variance": 0.012842, "average": 0.949111, "min": 0.434649}, "location": {"width": 645, "top": 432, "height": 40, "left": 113}, "words": "若2型尿病患者血清转氨酶升高(.T大于正常上限的2.5倍)时,则不应"}, {"probability": {"variance": 0.010325, "average": 0.946929, "min": 0.617705}, "location": {"width": 691, "top": 429, "height": 25, "left": 819}, "words": "见[药代动力学]),所以当本品与CYP2C8抑制剂联合应用时,由于可能增训与"}, {"probability": {"variance": 0.030555, "average": 0.885846, "min": 0.421349}, "location": {"width": 646, "top": 456, "height": 37, "left": 110}, "words": "服用本品所想者在初次服用本前应检测肝力,在任何临需要的情况"}, {"probability": {"variance": 0.025354, "average": 0.913891, "min": 0.372535}, "location": {"width": 473, "top": 451, "height": 25, "left": 818}, "words": "关不反应的风险,需要减低本品的成用剂量"}, {"probability": {"variance": 0.029123, "average": 0.895655, "min": 0.428543}, "location": {"width": 645, "top": 476, "height": 38, "left": 113}, "words": "下,需按关定期复查。对子治疗前或治疗中肝略高(I.T为正常上"}, {"probability": {"variance": 0.020054, "average": 0.905243, "min": 0.54033}, "location": {"width": 692, "top": 473, "height": 26, "left": 819}, "words": "本与C8诱导剂【如利福平)联合压药,可降低罗格列酮的血浆浓度(参"}, {"probability": {"variance": 0, "average": 0.997178, "min": 0.997178}, "location": {"width": 19, "top": 514, "height": 17, "left": 111}, "words": "的"}, {"probability": {"variance": 0.021284, "average": 0.900669, "min": 0.491293}, "location": {"width": 533, "top": 503, "height": 32, "left": 193}, "words": "5倍)的患者,应分手其肝升高的原因。对肝配释度升高的"}, {"probability": {"variance": 0.021557, "average": 0.928065, "min": 0.443359}, "location": {"width": 509, "top": 494, "height": 25, "left": 995}, "words": "因此,当本品与CYP2C8诱导剂联合应用时,应虑威"}, {"probability": {"variance": 0.034529, "average": 0.858571, "min": 0.364458}, "location": {"width": 609, "top": 526, "height": 32, "left": 108}, "words": "服用本品应怔重,适当缩短临床随访时间,增加肝酶检测频率,以"}, {"probability": {"variance": 0.013611, "average": 0.683968, "min": 0.567302}, "location": {"width": 43, "top": 518, "height": 22, "left": 818}, "words": "性测"}, {"probability": {"variance": 0.011502, "average": 0.942043, "min": 0.536195}, "location": {"width": 591, "top": 517, "height": 29, "left": 922}, "words": "化调整尿病的治疗方案。硝苯地平和口服避孕药(快雄醇机"}, {"probability": {"variance": 0.033026, "average": 0.849214, "min": 0.351835}, "location": {"width": 631, "top": 546, "height": 32, "left": 111}, "words": "高是否缓解或加重。如果服上本品的悲老AT大于止常上展3倍时:即日"}, {"probability": {"variance": 0.042482, "average": 0.848975, "min": 0.361113}, "location": {"width": 676, "top": 539, "height": 25, "left": 819}, "words": "诺)心3A途径代谢、四此与本品(毫克/次,每2否"}, {"probability": {"variance": 0.020865, "average": 0.919608, "min": 0.467532}, "location": {"width": 599, "top": 570, "height": 26, "left": 114}, "words": "查肝酶,若复查结果肝酶仍大于正常值3倍以二时,则应停止服目参品"}, {"probability": {"variance": 0.008209, "average": 0.977078, "min": 0.544871}, "location": {"width": 534, "top": 563, "height": 23, "left": 818}, "words": "用,不会上述药物产生具有临床意义的药代动力学影响"}, {"probability": {"variance": 0.033783, "average": 0.886015, "min": 0.387078}, "location": {"width": 657, "top": 588, "height": 38, "left": 110}, "words": "尚无临床试验以价服用格列附出现异常、肝损伤或艾疸的恐再扣罗"}, {"probability": {"variance": 0.042808, "average": 0.857587, "min": 0.361848}, "location": {"width": 679, "top": 584, "height": 26, "left": 822}, "words": "列本:格列本后病情稳定的糖尿病患者,本2毫次"}, {"probability": {"variance": 0.045484, "average": 0.897665, "min": 0.365238}, "location": {"width": 560, "top": 612, "height": 29, "left": 110}, "words": "格列酮的安全性。对于用曲格列后出现的者不推荐用"}, {"probability": {"variance": 0.015084, "average": 0.952599, "min": 0.43827}, "location": {"width": 435, "top": 605, "height": 26, "left": 1077}, "words": "克/日至10毫克/日)合用7,不会改变"}, {"probability": {"variance": 0.014356, "average": 0.933672, "min": 0.533476}, "location": {"width": 654, "top": 636, "height": 26, "left": 111}, "words": "如果患者出现肝功异常征兆知:不明原因的恶心、呕吐、腹痛、力食"}, {"probability": {"variance": 0.030193, "average": 0.890149, "min": 0.509238}, "location": {"width": 222, "top": 628, "height": 25, "left": 873}, "words": "小时的平均态血糖水平"}, {"probability": {"variance": 0.023689, "average": 0.915846, "min": 0.408644}, "location": {"width": 645, "top": 658, "height": 26, "left": 111}, "words": "或尿色加深,应检测肝酶。是否注续用本品治疗取决于临床及实验数果"}, {"probability": {"variance": 0.021252, "average": 0.902373, "min": 0.536214}, "location": {"width": 651, "top": 648, "height": 31, "left": 841}, "words": "甲双:对千受试者,本品(2毫克/次,每日2次)与二甲双五"}, {"probability": {"variance": 0.003749, "average": 0.964247, "min": 0.798154}, "location": {"width": 274, "top": 682, "height": 23, "left": 111}, "words": "评价。如出现黄疸,则停药"}, {"probability": {"variance": 0.037159, "average": 0.881934, "min": 0.401636}, "location": {"width": 679, "top": 672, "height": 31, "left": 827}, "words": "00毫克/日2次:合用4天,不会改变本品及二甲双的代"}, {"probability": {"variance": 0.018098, "average": 0.928202, "min": 0.659243}, "location": {"width": 135, "top": 698, "height": 22, "left": 822}, "words": "动力世参数"}, {"probability": {"variance": 0.007913, "average": 0.95905, "min": 0.620121}, "location": {"width": 360, "top": 727, "height": 22, "left": 110}, "words": "实验室测定:应定期检测空腹血及HbA1"}, {"probability": {"variance": 0.036866, "average": 0.831301, "min": 0.488714}, "location": {"width": 707, "top": 713, "height": 35, "left": 816}, "words": "何卡波糖:处上设试名服用阿皱糖(I00毫充/次,每日3次):对单"}, {"probability": {"variance": 0.023315, "average": 0.914796, "min": 0.371155}, "location": {"width": 509, "top": 748, "height": 22, "left": 110}, "words": "建议患者在用本品前检测肝功,后亦定检开功"}, {"probability": {"variance": 0.033362, "average": 0.882448, "min": 0.433798}, "location": {"width": 329, "top": 742, "height": 25, "left": 821}, "words": "剂口服本阳代动力学参数无影响"}, {"probability": {"variance": 0.003218, "average": 0.951878, "min": 0.859718}, "location": {"width": 84, "top": 770, "height": 19, "left": 110}, "words": "黄斑水肿"}, {"probability": {"variance": 0.041146, "average": 0.870282, "min": 0.353839}, "location": {"width": 508, "top": 763, "height": 25, "left": 824}, "words": "康量试者连服本品(8毫克次:1次)"}, {"probability": {"variance": 0.073812, "average": 0.764238, "min": 0.414608}, "location": {"width": 120, "top": 760, "height": 23, "left": 1376}, "words": "天,对苟"}, {"probability": {"variance": 0.041716, "average": 0.865776, "min": 0.367159}, "location": {"width": 649, "top": 789, "height": 28, "left": 114}, "words": "上市后在一些用本品或噻唑烷二类药物的2尿病考中,报告了黄斑水"}, {"probability": {"variance": 0.032995, "average": 0.878728, "min": 0.39109}, "location": {"width": 524, "top": 780, "height": 34, "left": 855}, "words": "呼75克/次每11次)的稳态药代动力学参数无影响"}, {"probability": {"variance": 0.015721, "average": 0.930829, "min": 0.441632}, "location": {"width": 588, "top": 812, "height": 26, "left": 171}, "words": "惠老主诉视物模糊和视力下降,但是些患者是经常规眼科检查所诊"}, {"probability": {"variance": 0.021941, "average": 0.917555, "min": 0.416782}, "location": {"width": 615, "top": 801, "height": 37, "left": 819}, "words": "华法朴:连续本品华法林对体的稳态药代动力学数无影响"}, {"probability": {"variance": 0.015601, "average": 0.915427, "min": 0.477775}, "location": {"width": 438, "top": 833, "height": 25, "left": 107}, "words": "断。在货斑水肿诊断时,大多数者伴有外周水肿"}, {"probability": {"variance": 0.04162, "average": 0.797488, "min": 0.412254}, "location": {"width": 181, "top": 834, "height": 28, "left": 585}, "words": "些思看停服烷二酮"}, {"probability": {"variance": 0.01457, "average": 0.933212, "min": 0.494787}, "location": {"width": 688, "top": 824, "height": 37, "left": 822}, "words": "乙醇:服用本品的2型糖尿病思者单次饮用中等量的乙醇,不会增加其急性低"}, {"probability": {"variance": 0.030766, "average": 0.921589, "min": 0.374597}, "location": {"width": 658, "top": 852, "height": 34, "left": 108}, "words": "类药物后,他们的黄斑水肿改善,按照美国尿病会的标准治疗指南,糖尿"}, {"probability": {"variance": 0.021575, "average": 0.913432, "min": 0.567286}, "location": {"width": 165, "top": 855, "height": 23, "left": 821}, "words": "血发生的危噬性"}, {"probability": {"variance": 0.02465, "average": 0.885273, "min": 0.439825}, "location": {"width": 663, "top": 876, "height": 32, "left": 105}, "words": "病患者应该进行常规的眼科检查。另外,如果尿病患者视力障碍,应素"}, {"probability": {"variance": 0.027732, "average": 0.907836, "min": 0.384619}, "location": {"width": 703, "top": 868, "height": 35, "left": 821}, "words": "l尼替丁:健块受试老服用雷尼丁(150毫克/次,每日2次)4天,不会"}, {"probability": {"variance": 0.027555, "average": 0.902951, "min": 0.364736}, "location": {"width": 628, "top": 895, "height": 34, "left": 110}, "words": "立即去眼科就诊,不管患者的基础用药或比他发现(参见不良事)"}, {"probability": {"variance": 0.020893, "average": 0.928417, "min": 0.405415}, "location": {"width": 688, "top": 891, "height": 35, "left": 822}, "words": "改变本品剂口或静脉给药的药代动力学参数,该结果表明肾肠道pH值升高"}, {"probability": {"variance": 0.000205, "average": 0.98887, "min": 0.964402}, "location": {"width": 78, "top": 919, "height": 20, "left": 110}, "words": "病人须知"}, {"probability": {"variance": 0.028332, "average": 0.882982, "min": 0.549975}, "location": {"width": 205, "top": 919, "height": 31, "left": 822}, "words": "不影响本品的口服吸收"}, {"probability": {"variance": 0.019473, "average": 0.921885, "min": 0.36538}, "location": {"width": 627, "top": 938, "height": 35, "left": 129}, "words": "饮食控制是2型糖尿病治疗的首选措施。甲热量、减轻体重和增加运动可"}, {"probability": {"variance": 0.031126, "average": 0.881484, "min": 0.436704}, "location": {"width": 654, "top": 934, "height": 38, "left": 824}, "words": "古非贝产:罗格列(4mg:一天一次)用CYP2C抑制剂吉非贝齐"}, {"probability": {"variance": 0.017064, "average": 0.932384, "min": 0.530971}, "location": {"width": 652, "top": 959, "height": 38, "left": 107}, "words": "提高胰岛素的敏感性,其不仅2型尿病的基本治疗,且可有效电保持药"}, {"probability": {"variance": 0.042536, "average": 0.783906, "min": 0.577662}, "location": {"width": 26, "top": 973, "height": 13, "left": 833}, "words": "60"}, {"probability": {"variance": 0.035631, "average": 0.829594, "min": 0.351147}, "location": {"width": 560, "top": 950, "height": 37, "left": 949}, "words": "大两次>7天后,与独用罗格到酮(4m一天一次】初"}, {"probability": {"variance": 0, "average": 0.998985, "min": 0.998778}, "location": {"width": 68, "top": 985, "height": 22, "left": 108}, "words": "物疗效"}, {"probability": {"variance": 0.013813, "average": 0.946035, "min": 0.364713}, "location": {"width": 700, "top": 977, "height": 38, "left": 819}, "words": "比,可增加罗格列的AUC2倍。如果发生潜在的与罗格列剂量相关的不良事"}, {"probability": {"variance": 0.033256, "average": 0.873937, "min": 0.360862}, "location": {"width": 651, "top": 1004, "height": 38, "left": 110}, "words": "●2型糖尿病患者应抚要求控制饮食,并定期监测!血和化血红蛋白:当"}, {"probability": {"variance": 0.012027, "average": 0.947558, "min": 0.504821}, "location": {"width": 488, "top": 1004, "height": 32, "left": 821}, "words": "件,当使用古非贝齐时,应减少罗格列酮的使用剂量"}, {"probability": {"variance": 0.026042, "average": 0.917009, "min": 0.459241}, "location": {"width": 317, "top": 1026, "height": 25, "left": 107}, "words": "患者,需治疗2周后方可见血降低"}, {"probability": {"variance": 0.003548, "average": 0.961778, "min": 0.781124}, "location": {"width": 298, "top": 1028, "height": 37, "left": 464}, "words": "3个月可观察到疗效,同时告知者"}, {"probability": {"variance": 0.003204, "average": 0.971806, "min": 0.785436}, "location": {"width": 695, "top": 1023, "height": 35, "left": 818}, "words": "【药物过】日前尚缺乏人体药物过量的资料。健康受试者单剂口服本品最高"}, {"probability": {"variance": 0.010486, "average": 0.935107, "min": 0.645096}, "location": {"width": 649, "top": 1046, "height": 41, "left": 111}, "words": "开始服用本品前需检测肝功,服药后应根据医生医嘱定期复查肝酶。在有任河"}, {"probability": {"variance": 0.00329, "average": 0.980366, "min": 0.735849}, "location": {"width": 405, "top": 1046, "height": 31, "left": 1105}, "words": "旦发生药物过量,应根据病人的临床表现给予"}, {"probability": {"variance": 0.033103, "average": 0.866801, "min": 0.454067}, "location": {"width": 646, "top": 1068, "height": 43, "left": 111}, "words": "临床需要的情况下,高按医配定复点。想者出现不明瓯因的症状,如恶"}, {"probability": {"variance": 0.009645, "average": 0.92743, "min": 0.686164}, "location": {"width": 244, "top": 1052, "height": 31, "left": 821}, "words": "达20毫克,仍可很好耐受"}, {"probability": {"variance": 0.011244, "average": 0.937458, "min": 0.582154}, "location": {"width": 509, "top": 1089, "height": 32, "left": 110}, "words": "心、呕、腹、乏力、食或尿色加,应立即就"}, {"probability": {"variance": 0.016635, "average": 0.918189, "min": 0.682128}, "location": {"width": 147, "top": 1078, "height": 23, "left": 824}, "words": "柜应的文持治疗"}, {"probability": {"variance": 0.021895, "average": 0.918927, "min": 0.359129}, "location": {"width": 633, "top": 1110, "height": 43, "left": 113}, "words": "●在服用本品治打期如上现体重骤增、肿、气短或其心力衰竭的症状"}, {"probability": {"variance": 0.000294, "average": 0.980993, "min": 0.963059}, "location": {"width": 126, "top": 1098, "height": 28, "left": 821}, "words": "药理理】"}, {"probability": {"variance": 0.008885, "average": 0.957143, "min": 0.667501}, "location": {"width": 228, "top": 1134, "height": 22, "left": 110}, "words": "时,需及时咨询医生意见"}, {"probability": {"variance": 0.000579, "average": 0.969689, "min": 0.928863}, "location": {"width": 78, "top": 1123, "height": 22, "left": 824}, "words": "药理作用"}, {"probability": {"variance": 0.00827, "average": 0.952376, "min": 0.736402}, "location": {"width": 256, "top": 1154, "height": 26, "left": 113}, "words": "●本品可于空腹或进餐时服用"}, {"probability": {"variance": 0.027362, "average": 0.911055, "min": 0.415765}, "location": {"width": 688, "top": 1132, "height": 38, "left": 825}, "words": "本品属唑烷二类抗糖尿病药,通过提高胰岛米的敏感性面有效地控制血糖"}, {"probability": {"variance": 0.010881, "average": 0.919878, "min": 0.661546}, "location": {"width": 408, "top": 1159, "height": 35, "left": 824}, "words": "本品为过氧化物酶体增殖激活受体￥(FPAR"}, {"probability": {"variance": 0.024145, "average": 0.912449, "min": 0.517864}, "location": {"width": 220, "top": 1156, "height": 25, "left": 1287}, "words": "的高选择性.强效激动剂"}, {"probability": {"variance": 0.04668, "average": 0.878412, "min": 0.362751}, "location": {"width": 633, "top": 1174, "height": 47, "left": 132}, "words": "对患者其家科悦明,与其它口服降药合用可能发生低的危险性"}, {"probability": {"variance": 0.016992, "average": 0.947111, "min": 0.503857}, "location": {"width": 418, "top": 1196, "height": 31, "left": 110}, "words": "低血症状及处理,以及易引起低血发生的原因"}, {"probability": {"variance": 0.025518, "average": 0.891014, "min": 0.490122}, "location": {"width": 700, "top": 1175, "height": 41, "left": 822}, "words": "人类的EAP受体存在于胰岛素的主靶组织如肝脏、脂肪和肌肉组织,本品激"}, {"probability": {"variance": 0.019335, "average": 0.924581, "min": 0.428832}, "location": {"width": 643, "top": 1216, "height": 50, "left": 129}, "words": "本品可使伴有胰岛素抵抗的绝经前期和无排卵型妇女恢复排卵,比建议患者"}, {"probability": {"variance": 0.012276, "average": 0.958491, "min": 0.462094}, "location": {"width": 688, "top": 1198, "height": 40, "left": 824}, "words": "活PPR-Y核受体,可对参与葡萄糖生成、转运和利用的胰岛素反应基因的转"}, {"probability": {"variance": 0.026848, "average": 0.880464, "min": 0.366981}, "location": {"width": 667, "top": 1238, "height": 52, "left": 110}, "words": "服用本品时,需采收避孕措施以上不良反应还来经过专门的临床究,比"}, {"probability": {"variance": 0.020526, "average": 0.929448, "min": 0.485823}, "location": {"width": 697, "top": 1219, "height": 46, "left": 822}, "words": "进行调挠。此外,PPAR-￥反应基区也参与脂肪酸代的调节。在本品临床"}, {"probability": {"variance": 0.034814, "average": 0.882967, "min": 0.523206}, "location": {"width": 141, "top": 1260, "height": 23, "left": 113}, "words": "其发生率尚末知"}, {"probability": {"variance": 0.02937, "average": 0.89276, "min": 0.351829}, "location": {"width": 704, "top": 1239, "height": 44, "left": 819}, "words": "究中,空腹(FPG)和 Hbalc的检测结果表明,本品可改善血树控制情"}, {"probability": {"variance": 0.027822, "average": 0.928302, "min": 0.416838}, "location": {"width": 211, "top": 1281, "height": 23, "left": 111}, "words": "对驾驶和机器操作的响"}, {"probability": {"variance": 0.018257, "average": 0.912401, "min": 0.484884}, "location": {"width": 681, "top": 1263, "height": 43, "left": 822}, "words": "况,同时伴有皿胰岛素和C肽水平降低,也可使半后血对和岛素水平下降"}, {"probability": {"variance": 0.009057, "average": 0.933944, "min": 0.742887}, "location": {"width": 271, "top": 1305, "height": 23, "left": 114}, "words": "对驾驶和机器操作的影响尚末知"}, {"probability": {"variance": 0.019181, "average": 0.935994, "min": 0.385801}, "location": {"width": 478, "top": 1292, "height": 34, "left": 824}, "words": "本品对血控的改作用较持久,可持达52周:"}, {"probability": {"variance": 0.011081, "average": 0.931794, "min": 0.653265}, "location": {"width": 236, "top": 1324, "height": 25, "left": 107}, "words": "【孕妇及哺乳期幻女月药1"}, {"probability": {"variance": 0.036045, "average": 0.905644, "min": 0.359152}, "location": {"width": 701, "top": 1305, "height": 43, "left": 822}, "words": "2型尿病的主病例生理学特征为胰岛素抵抗,本品的抗尿病作用已在2型"}, {"probability": {"variance": 0.004883, "average": 0.97465, "min": 0.743254}, "location": {"width": 247, "top": 1348, "height": 22, "left": 111}, "words": "妊娠期药品安全分类日录级"}, {"probability": {"variance": 0.027571, "average": 0.912707, "min": 0.374738}, "location": {"width": 694, "top": 1330, "height": 38, "left": 828}, "words": "尿病的动物模型于靶组织的胰岛素抵抗而出现在高血糖症和/或量下降"}, {"probability": {"variance": 0.019619, "average": 0.937133, "min": 0.406799}, "location": {"width": 658, "top": 1365, "height": 56, "left": 110}, "words": "无论是否存在药物暴,听有均有发生出生缺陷、产或其他不良结果的"}, {"probability": {"variance": 0.020755, "average": 0.896204, "min": 0.542145}, "location": {"width": 695, "top": 1348, "height": 43, "left": 825}, "words": "中得到显示,可有效降低b/ub肥胖小鼠、db/dbw尿病小鼠和 fe!fa Zucker肥"}, {"probability": {"variance": 0.009646, "average": 0.947862, "min": 0.588587}, "location": {"width": 640, "top": 1385, "height": 56, "left": 110}, "words": "背景风险,对于高血糖妊娠该风险更,但可通过良好的代谢控来降低风"}, {"probability": {"variance": 0.018499, "average": 0.906146, "min": 0.555256}, "location": {"width": 698, "top": 1371, "height": 43, "left": 825}, "words": "昨大鼠的山,减轻其高胰血症,并可延缓dbdb小鼠和 tucker肥胖大鼠模"}, {"probability": {"variance": 0.017807, "average": 0.931972, "min": 0.500103}, "location": {"width": 688, "top": 1394, "height": 41, "left": 828}, "words": "魅的民病发展。动物究提示,本品的抗尿病作用是通过提高肝脏、肌肉和"}], "language": -1}